HER2-Negative Breast Carcinoma — Trials

HER2-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 29
Recruiting: 21
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06016738	OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01)	active not recruiting	Phase 3	510	Olema Pharmaceuticals, Inc.INDUSTRY	26	Aug 13, 2026	clinicaltrials
NCT04379570	Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	active not recruiting	Phase 3	1,167	Alliance for Clinical Trials in OncologyOTHER	1